Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL27545073 | 0.95 | ALDH1A1 (0.54) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL28161534 | 0.83 | TSHR (0.61) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL17331852 | 0.83 | KDM4E (0.60) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL3983002 | 0.81 | NR4A2 (0.50) | TSHRKDM4EALDH1A1GAAMEN1 | |
| SCHEMBL27930822 | 0.81 | ALDH1A1 (0.55) | TSHRALDH1A1HPGDKMT2ACYP1A2 | |
| SCHEMBL8123256 | 0.81 | CREBBP (0.45) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL17331579 | 0.79 | KDM4E (0.56) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL17331543 | 0.79 | KDM4E (0.56) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL26413736 | 0.78 | TSHR (0.48) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL20226860 | 0.78 | KMT2A (0.45) | TSHRKDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102977097-A | Aryne-based substituted indolizine derivative and preparation method and applications thereof | UNIV SHAOXING | 2013-03-20 | — | — | CN | claimed |
| CN-102977126-A | Dual-indolizine substitutive derivative as well as preparation method and use thereof | UNIV SHAOXING | 2013-03-20 | — | — | CN | claimed |
| US-20250042900-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4499058-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | Tactogen Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-2800745-B1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORY, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| CN-102977097-B | A kind of sweet-smelling alkynyl substituted indole oxazine derivative and its production and use | SHAOXING UNIVERSITY (CN) | 2015-10-14 | — | — | CN | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-2800745-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORY, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | Phenex Pharmaceuticals AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| CN-102977126-B | Dual-indolizine substitutive derivative as well as preparation method and use thereof | UNIV SHAOXING | 2014-07-02 | — | — | CN | disclosed |
| WO-2013079223-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORϒ, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2013-06-06 | — | — | WO | disclosed |
| CN-102977097-A | Aryne-based substituted indolizine derivative and preparation method and applications thereof | UNIV SHAOXING | 2013-03-20 | — | — | CN | disclosed |
| CN-102977126-A | Dual-indolizine substitutive derivative as well as preparation method and use thereof | UNIV SHAOXING | 2013-03-20 | — | — | CN | disclosed |
| EP-0471609-B1 | Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them | SANOFI SA (FR) | 1996-11-27 | — | — | EP | disclosed |
| EP-0471609-A1 | Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them | SANOFI (FR) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | TSHR 152/4885KDM4E 2519/4885ALDH1A1 2097/4885 |
| US-20250042900-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TPH2, TPH1, IDO2 | TSHR 1451/4885KDM4E 3156/4885ALDH1A1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.